Association of IL4Rsingle-nucleotide polymorphisms with rheumatoid nodules in African Americans with rheumatoid arthritis

Table 1 Baseline sociodemographic, clinical, and laboratory characteristics of RA patients in the CLEAR registries as a function of the presence of erosions or rheumatoid nodules

	Radiographic erosions			Rheumatoid nodules
Variable	Present n = 185	Absent n = 276	P ^f	Present n = 156	Absent n = 593	P ^f
Age at RA onset, years, mean (SD)	45.3 (14.5)	48.3 (12.6)	0.02	45.6 (12.6)	47.8 (13.6)	0.06
Disease duration,^a years, median (IQR^b)	3.8 (1.2-15.5)	1.2 (6.0-2.0)	<0.0001	7.5 (1.3-15.6)	1.8 (0.8-8.0)	<0.001
Smoking, ever,^c n (%)	98 (54.4)	139 (51.9)	0.59	95 (61.7)	295 (50.3)	0.01
HAQ^d score, median (IQR)	2.0 (1.3-2.4)	1.8 (0.9-2.4)	0.27	2.1 (1.3-2.6)	1.8 (1.0-2.4)	0.01
Joint-space narrowing at baseline, present (score >0), n (%)	132 (71.4)	34 (12.3)	<0.001	48 (53.3)	116 (31.9)	<0.001
Rheumatoid factor positive, n (%)	145 (87.3)	182 (74.3)	0.001	127 (90.7)	418 (77.1)	<0.001
Anti-CCP antibody positive, n (%)	148 (81.3)	159 (59.3)	<0.001	127 (84.1)	375 (65.2)	<0.001
Abnormal C-reactive protein (>5 mg/L), n (%)	94 (51.9)	126 (46.5)	0.26	77 (58.8)	238 (44.7)	<0.004
HLA-DRB1 present,^e n (%)	78 (42.9)	113 (41.1)	0.71	64 (43.2)	234 (39.9)	0.45
Methotrexate use, ever,^c n (%)	149 (82.3)	175 (64.6)	<0.001	127 (81.9)	423 (72.2)	0.01

^aDisease duration at enrollment: duration between self-reported onset of symptoms and date of enrollment; ^bIQR interquartile range (25^th and 75^th); ^ccurrent or past; ^dHeath Assessment Questionnaire; ^eHLADRB1 was made to determine SE positive; ^fTwo-tailed P value by independent-sample t test, Wilcoxon rank-sum test, or χ² test for proportions, as appropriate and wherever applicable, missing data were excluded from the denominator for calculating percentage and P value.

ISSN: 1478-6362